Eli Lilly says it could pull tens of millions of dollars invested in Australian clinical trials unless the federal government dramatically cuts the time it takes to put new drugs onto the Pharmaceutical Benefits Scheme.
The warning from one of the drugmaker’s top executives, visiting Australia this week, builds on pressure from the powerful pharmaceutical lobby for better deals for the medicines they sell domestically and comes at the same time as Donald Trump prepares to place tariffs on drug imports.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.